Galapagos NV reports results for the quarter ended in September - Earnings Summary

Lakefront Biotherapeutics NV

02/11/2023 22:16

* Galapagos NV  GLPG.AS  reported quarterly adjusted
earnings of
39 cents​​ per share for the quarter ended in September, higher
than the same quarter last year, when the company reported EPS
of 33 cents.  The mean expectation of three analysts for the
quarter was for a loss of 96 cents per share. Wall Street
expected results to range from €-1.26 to -66 cents per share.
    * Revenue fell 11.9% to €120.03 million from a year ago;
analysts
expected €82.15 million. 
    * Galapagos NV's reported EPS for the quarter was 39 cents​.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 29.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Galapagos NV is
€40.50 
This summary was machine generated from LSEG data November 2 at
10:16 p.m. UTC. ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.96          0.39           Beat
 Jun. 30 2023      -0.83          0.08           Beat
                                  0.35           
 Dec. 31 2022      -0.53          -3.16          Missed